

# hCD38(2)

<b>Nomenclature</b>	C57BL/6Smoc- <i>Cd38</i> <sup>em2(CD38)Smoc</sup>
<b>Cat. NO.</b>	NM-HU-190059
<b>Strain State</b>	Repository Live

## Gene Summary

<b>Gene Symbol</b> CD38	<b>Synonyms</b>	I-19; ADPRC 1; Cd38-rs1
	<b>NCBI ID</b>	<a href="#">12494</a>
	<b>MGI ID</b>	<a href="#">107474</a>
	<b>Ensembl ID</b>	<a href="#">ENSMUSG00000029084</a>
	<b>Human Ortholog</b>	CD38

## Model Description

The endogenous mouse Cd38 gene was replaced by human CD38 gene. While hCD38 mice (Stock No. NM-HU-00113) have been pulled from shelves for some reasons.

**Research Application:** Immunotherapy, cancer research, drug screening

\*Literature published using this strain should indicate: hCD38(2) mice (Cat. NO. NM-HU-190059) were purchased from Shanghai Model Organisms Center, Inc..

## Validation Data




Fig1. hCD38 is highly expressed on both B cells and T cells in human PBMC.




Fig2. m/hCD38 is highly expressed on blood and spleen-derived B cells in hCD38 knockin mice.




Fig3. m/hCD38 can be detected on blood-derived T cells in hCD38 knockin mice.







Fig4. m/hCD38 can be detected on spleen-derived T cells in hCD38 knockin mice.



**Fig5. *In vivo* anti-tumor effect of Daratumumab in hCD38 knockin mice.** Homozygous humanized CD38 mice were inoculated with E.G7-OVA T lymphoma cells. The results showed: Daratumumab, a drug targeting human CD38, showed a very significant anti-tumor effect, demonstrating that the humanized CD38 mouse model is a good *in vivo* model for validating the efficacy of antibodies targeting human CD38. ( In cooperation with Crownbio)



**Fig6. Binding assay of Daratumumab to hCD38-derived B cells.** ( In cooperation with Crownbio)



**Fig7. Binding assay of Daratumumab to hCD38-derived T cells.** ( In cooperation with Crownbio)